RNA, U6atac small nuclear 24, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC24P profile across patient tissues and cancer cell-line models. RNU6ATAC24P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC24P is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, RNU6ATAC24P RNA expression shows 17,100 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight COAD, STAD, and DLBC as cancer lineages where RNU6ATAC24P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC24P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC24P survival associations across molecular data types. RNU6ATAC24P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC24P RNA expression–survival associations across cancer types. High RNU6ATAC24P expression shows unfavorable associations in COAD and BLCA, but favorable associations in BRCA, READ, LUAD and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RNU6ATAC24P RNA expression.
This table summarizes RNU6ATAC24P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC24P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC24P shows higher tumor expression in STAD, LUSC, LIHC and KIRC. The STAD box plot shows higher RNU6ATAC24P RNA expression in tumor versus normal tissue (log2 FC = +0.540, t-test p = .045).
This table shows molecular features associated with RNU6ATAC24P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC24P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
